Oct. 24 at 8:32 PM
$TPST The track record of the companies Stephen Brady was instrumental in selling is indeed exceptional:
• Proteolix's drug, Kyprolis (carfilzomib), became a game-changing, standard-of-care drug for Multiple Myeloma and was the core asset that drove the subsequent
$10 billion acquisition of Onyx Pharmaceuticals.
• Immune Design provided valuable, next-generation platform technology to Merck, a leader in immunotherapy, to advance their cancer and vaccine pipelines.
His current position at Tempest Therapeutics—where the company is now officially "exploring strategic alternatives" (i.e., a sale or major partnership) after generating promising clinical data—fits perfectly with this successful playbook of advancing assets to a high-value inflection point for a strategic exit.
